Onconova Therapeutics, Inc. (NASDAQ:ONTX) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET
Company Participants
Bruce Mackle - Investor Relations, LifeSci Advisors
Steve Fruchtman - President & Chief Executive Officer
Mark Gelder - Chief Medical Officer
Mark Guerin - Chief Operating Officer & Chief Financial Officer
Conference Call Participants
Charles Zhu - Guggenheim
Chun Lung - Ladenburg
Robert LeBoyer - Noble Capital Markets
Operator
Ladies and gentlemen, thank you for standing by. Welcome to the Onconova Therapeutics Second Quarter 2022 Financial Results and Business Update Conference Call. At this time all participants are in listen only mode. Following management's prepared remarks, we will hold a question-and-answer session. [Operator Instructions] As a reminder, this call is being recorded today, August 11, 2022.
At this time, I'd like to turn the call over to Bruce Mackle of LifeSci Advisors, please go ahead.
Bruce Mackle
Thank you, operator, and welcome everyone to Onconova’s second quarter 2022 financial results and business update conference call. Earlier this afternoon Onconova issued a press release reporting its financial results and business progress. If you have not yet seen this press release it is available in the Investors and Media section of the company's website at www.onconova.com. Following my introduction Onconova’s President and CEO, Dr. Steve Fruchtman will provide an overview of the company's recent highlights and future outlook, followed by Chief Medical Officer, Dr. Mark Gelder, who will discuss progress across Onconova’s pipeline. And lastly, Chief Operating Officer and Chief Financial Officer, Mark Guerin will report the company's second quarter financial results. These prepared remarks will then be followed by a question-and-answer session.
Before turning the call over to Onconova’s management team, I'd like to remind everyone that statements made during this conference call will include forward-looking statements under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties that can cause actual results to differ materially. Forward looking statements speak only as of the date they are made, as the underlying facts and circumstances may change, except as required by law Onconova disclaims any obligation to update these forward-looking statements to reflect future information, events or circumstances. For more information on forward looking statements, please review the disclaimer in today's press release and the risk factors in the company's SEC filings.
With that it is my pleasure to turn the call over to Steve.
Steve Fruchtman